Neuropace Stock Today
| NPCE Stock | USD 13.95 0.12 0.87% |
PerformanceWeakest
| Odds Of DistressRisky
|
Neuropace is trading at 13.95 as of the 5th of March 2026, a 0.87 percent increase since the beginning of the trading day. The stock's lowest day price was 13.01. Neuropace has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 5th of December 2025 and ending today, the 5th of March 2026. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 22nd of April 2021 | Category Healthcare | Classification Health Care |
NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 33.31 M outstanding shares of which 869.26 K shares are now shorted by private and institutional investors with about 5.02 trading days to cover. More on Neuropace
Moving together with Neuropace Stock
Moving against Neuropace Stock
Neuropace Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Joel Becker | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, Neuropace can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Neuropace's use of financial leverage and reveals what portion of Neuropace's asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neuropace (NPCE) is traded on NASDAQ Exchange in USA and employs 209 people. Neuropace is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 460.65 M. Neuropace conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 33.31 M outstanding shares of which 869.26 K shares are now shorted by private and institutional investors with about 5.02 trading days to cover.
Neuropace currently holds about 92.41 M in cash with (17.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72.
Check Neuropace Probability Of Bankruptcy
Ownership AllocationNeuropace maintains a total of 33.31 Million outstanding shares. The majority of Neuropace outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neuropace to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neuropace. Please pay attention to any change in the institutional holdings of Neuropace as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Neuropace Ownership Details
Neuropace Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Fmr Inc | 2025-12-31 | 624.9 K | |
| Geode Capital Management, Llc | 2025-09-30 | 559.7 K | |
| State Street Corp | 2025-09-30 | 407.8 K | |
| Silvercrest Asset Management Group Llc | 2025-12-31 | 396.6 K | |
| Nantahala Capital Management, Llc | 2025-12-31 | 295.1 K | |
| Divisadero Street Capital Management, Lp | 2025-09-30 | 292.8 K | |
| Northern Trust Corp | 2025-09-30 | 236.5 K | |
| Walleye Trading Advisors, Llc | 2025-12-31 | 228.8 K | |
| Renaissance Technologies Corp | 2025-12-31 | 222.3 K | |
| Polar Capital Holdings Plc | 2025-09-30 | 3.1 M | |
| Soleus Capital Management, L.p. | 2025-09-30 | 3 M |
Neuropace Historical Income Statement
Neuropace Stock Against Markets
Neuropace Corporate Management
| Irina Ridley | Chief Secretary | Profile | |
| Chi Nguyen | VP Marketing | Profile | |
| Kelley Nicholas | Vice Sales | Profile | |
| Michael Favet | CEO Pres | Profile | |
| Katie Keller | Vice Marketing | Profile | |
| Patrick Williams | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value - what Neuropace's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.